TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Ketamine for Pain With Gastric Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients undergoing laparoscopic gastric bypass at Mayo Clinic in Arizona~2. BMI is ≥ 35 kg/m2~3. Consent is able to be obtained as per Mayo Clinic policy~Exclusion Criteria:~1. Intolerance to ketamine~2. History of schizophrenia, schizoaffective disorder, or other psychiatric diagnosis with psychotic features~3. Presence of unstable cardiovascular disease (presence of acute coronary syndrome, unstable angina, hypertension emergency, acute transient ischemic attack (TIA) or stroke)~4. Presence of acute elevation of intracranial or intraocular pressure~5. Presence of seizure disorder~6. History of substance abuse or addiction~7. Creatinine greater than 1.5 mg/dL~8. End-stage liver disease~9. Pregnancy~10. Patients with chronic pain and/or chronic opioid therapy will not be excluded to more closely replicate the study patient population of interest. However, patients taking greater than 50 morphine equivalents (ME) per day for greater than 1 month prior to surgery will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Ketamine Therapy (Type: EXPERIMENTAL): 1. Ketamine 0.3 mg/kg (IBW) bolus with induction.~2. Ketamine infusion 0.2 mg/kg/hr. (IBW) initiated after induction and terminated after 24 hours.~3. Ketamine infusion will not be titrated.~4. Remaining care will be identical to standard therapy group.
- Standard Therapy (Type: ACTIVE_COMPARATOR): 1. Calculation ideal body weight (IBW)~2. Pre-op dexamethasone~3. Pre-op midazolam at discretion of anesthesiologist~4. Anesthesia Induction - Propofol and fentanyl, anesthesiologist discretion. Neuromuscular block with succinylcholine and/or rocuronium at discretion of anesthesiologist. Orotracheal intubation.~5. Anesthesia Maintenance - Sevoflurane/rocuronium. Addl. doses of fentanyl, discretion of anesthesiologist.~6. Emergence from anesthesia - Acetaminophen, Ketorolac and Ondansetron unless contraindicated. Sugammadex depending on twitch response per drug manufacturer recommended protocol.~7. Post-Op Analgesia - Hydromorphone, acetaminophen and ketorolac~8. Other post-op care as per usual surgical routine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 70, or age ≥ 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization Classification.~2. Eastern Cooperative Oncology Group Performance Status of 0-2~3. Cardiac ejection fraction ≥45%~4. Males are eligible to enter and participate in the study if they have either had a prior vasectomy or agree to avoid sexual activity or use adequate contraception from screening through two months post the last dose of decitabine~Exclusion Criteria:~1. Patients with acute promyelocytic leukemia~2. Life expectancy ≤3 months~3. Prior use of any hypomethylating agent or cytarabine~4. Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy~5. Serum creatinine \> 2x upper limit of normal~6. Aspartate aminotransferase (AST),alanine aminotransferase (ALT), or total bilirubin \> 5x upper limit of normal~7. History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~8. Patient may not be receiving any other antineoplastic agents (hydroxyurea is allowed)~9. Concurrent malignancy. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled.~10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- decitabine and cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine-Ketamine Versus Ketamine for Induction of Anesthesia in Septic Shock Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients aged above 18 years~* With septic shock~* Scheduled for general anesthesia~Exclusion Criteria:~* Patients under 18 years~* Burn patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine group (Type: ACTIVE_COMPARATOR): This group will receive induction of anesthesia using ketamie full dose 1 mg/kg, midazolam 0.05 mg/Kg, and normal saline 10 mL.
- Lidocaine-ketamine group (Type: EXPERIMENTAL): This group will receive induction of anesthesia using Ketamie half dose 0.5 mg/kg, midazolam 0.05 mg/Kg, and lidocaine 1 mg/Kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Versus Palpation Guided Cricothyrotomy With Poorly Defined Anatomical Landmarks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Residents who are novice to the application of ultrasound in difficult airway scenarios~* Cadavers with difficult and imposible landmarks identification~Exclusion Criteria:~* Anethesiologist with previous experience in CT, manual or ultrasound assisted~* Patients with easily identifiable landmarks

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cricothyrotomy using Digital Palpation (Type: ACTIVE_COMPARATOR): Group-1 will perform Cricothyrotomy using conventional digital palpation technique
- Ultrasound guided cricothyrotomy group (Type: EXPERIMENTAL): Group-2 Ultrasound guided cricothyrotomy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female, 18 to 75 years of age~* Overweight or obese with a body mass index (BMI) ≥ 25 kg/m2~* Presumed NASH diagnosed by prior biopsy and/or imaging criteria~* Written informed consent~Key Exclusion Criteria:~* History or clinical evidence of chronic liver diseases other than NAFLD~* History or known clinical evidence of cirrhosis, esophageal varices, hepatic decompensation or other severe liver impairment,~* History of liver transplant, or current placement on a liver transplant list~* Current diagnosis or history of pituitary or thyroid disorders - except for patients with primary hypothyroidism on a stable dose of thyroid hormone replacement therapy.~* Abnormal TSH or free T4 levels~* Weight loss of \> 5% total body weight within 3 months prior to Screening~* Uncontrolled diabetes~* Uncontrolled hyperlipidemia~* Unstable cardiovascular disease~* Excessive alcohol consumption~Other protocol-defined I/E criteria that apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: TERN-501 1 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 2: TERN-501 3 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 3: TERN-501 6 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 4: TERN-501 3 mg + TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 5: TERN-501 6 mg + TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 6:TERN-101 10 mg (Type: EXPERIMENTAL): Orally administered.
- Arm 7: Matching placebo (Type: PLACEBO_COMPARATOR): Orally administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide in Pediatric Inflammatory Bowel Diseases.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children, adolescents and young adults aged 2 to 20 with chronic refractory moderate to severe inflammatory bowel disease, referred by the six pediatric gastroenterological centres participating in the study.~Definition of patient with refractory disease:~* Patients with active disease despite steroid therapy (prednisone at a dose 2 mg/kg/die, maximum 60mg/day, or equivalent) for 8 weeks and/or an immunosuppressive of proven efficacy (azathioprine o 6-mercaptopurine for 4 months; methotrexate for 3 months; Infliximab at the dose of 5 mg/kg at week 0,2,6 weeks; cyclosporine at the dose of 2mg/kg/day for 4 weeks or 1 week at 1m/kg/day EV) or patients exhibiting intolerance to these drugs which prevent them from continuing treatment.~Exclusion Criteria:~* Patients with ileostomy or colostomy.~* Disease requiring immediate surgical intervention.~* Severe ulcerative colitis or toxic megacolon.~* Contraindications to using thalidomide (on-going pregnancy, neuropathy) .~* Any of the following conditions: active infection, stool culture positive for enteric pathogens, tumors, HIV, transplanted organ, or non-controlled disease of the kidney, liver, endocrine system, heart, blood, nervous system or brain.~* Patients being treated with other drugs as part of an experimental study.~* Patients treated with infliximab in the previous eight weeks.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Thalidomide
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participants with type 2 diabetes mellitus diagnosed for at least 1 year.~* Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening.~Exclusion criteria:~* Age \< legal age of adulthood (18 years).~* Screening HbA1c \<7% or \>10%.~* Screening FPG \>250 mg/dL (\>13.9 mmol/L).~* Pregnancy or lactation, women of childbearing potential with no effective contraceptive method.~* Type 1 diabetes mellitus.~* Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening.~* Use of insulin within the last 6 months.~* Previous use of insulin, except for episode(s) of short-term treatment (≤15 consecutive days) due to intercurrent illness.~* Amylase and/or lipase \>3 times the upper limit of the normal laboratory range (ULN) at screening.~* Calcitonin ≥20 pg/ml (5.9 pmol/l) at screening.~* Alanine Transferase (ALT) \>3 ULN at screening.~* History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.~* Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes).~* Uncontrolled or inadequately controlled hypertension at the time of screening with a resting supine systolic or diastolic blood pressure \>180 mmHg or \>110 mmHg, respectively.~* Within the last 6 months prior to screening: history of heart failure requiring hospitalization, myocardial infarction, or stroke. Planned coronary, carotid or peripheral artery revascularisation procedures.~* Body Mass Index (BMI) ≤20 or \>40 kg/m\^2.~* Any previous treatment with lixisenatide~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine/Lixisenatide Fixed Ratio Combination (FRC) (Type: EXPERIMENTAL): FRC injected once daily (QD) for 24 weeks. Dose individually adjusted.
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine QD for 24 weeks. Dose individually adjusted.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Testosterone in Women With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female, age 18-75~* Written informed consent~* Meet Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (by Structured Clinical Interview for DSM-IV (SCID)) for Major Depressive Disorder~* Meet DSM-IV criteria for a current major depressive episode, as assessed by SCID~* Montgomery-Asberg Depression Rating Scale (MADRS) greater than or equal to 16 at baseline visit~* Currently treated with SSRI or SNRI, with or without adjunctive therapy, at an adequate dose (see adequate dose table below) for at least six weeks~Exclusion Criteria:~* Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (to include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy)~* Serious suicide or homicide risk, as assessed by evaluating clinician~* Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic (including uncontrolled seizure disorder)~* Substance use disorder active within last six months~* Psychotic features (current episode or lifetime), as assessed by SCID~* Laboratory evidence of untreated hypothyroidism~* If treated hypothyroidism, significant change in levo-thyroxine dose within the prior three months~* If receiving oral estrogen therapy, including oral contraceptives or transdermal estrogen therapy, significant change in dose in the prior three months~* Use of androgens or androgen precursors, including testosterone, Dehydroepiandrosterone (DHEA) and methyltestosterone, within the prior three months~* Any investigational psychotropic drug within the last two weeks~* In the judgment of the study clinician, unlikely to be able to participate safely throughout the study period (three or more episodes of self-harm in the past year, documented history of poor treatment adherence, or frequent missed appointments (greater than 50%) in the past year)~* Alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal.~* Creatinine greater than 1.5 times upper limit of normal~* History of a hormone-responsive cancer~* History of congestive heart failure~* MADRS greater than 31

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Testosterone (Type: ACTIVE_COMPARATOR): Testosterone patch delivering 300mcg daily for 8-weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Had been receiving a stable dose and regimen of an α-glucosidase inhibitor for the last 4 weeks or longer before the start of the screening phase (Week -8) and during the screening phase.~* Had a glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of the screening phase (Week -4).~* Had HbA1c differences within 10.0% at the start of the screening phase (Week -8) and 4 weeks after the start of the screening phase (Week -4) from the HbA1c value at the start of the screening phase.~* Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of the screening phase (Week -8).~Exclusion Criteria:~* Had received any antidiabetic drug other than α-glucosidase inhibitors within the last 4 weeks before the start of the screening phase (Week -8) or during the screening phase.

- Gender: ALL
- Minimum Age: 33 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Voglibose 0.2 mg TID (Type: ACTIVE_COMPARATOR): None
- Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None
- Alogliptin 25 mg QD and Voglibose 0.2 mg TID (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Has mild to moderate hypertension with mean sitting systolic blood pressure (SBP) of \>130 and ≤165 mmHg without hypertensive medication for Parts A, B and D, and \>135 and ≤165 mmHg without hypertensive medication for Part E~* Parts A and B: Has body mass index (BMI) ≥18 and ≤35 kg/m\^2; Part D: Has BMI \>35 and ≤50 kg/m\^2; Part E: Has BMI ≥18 kg/m\^2 and ≤50 kg/m\^2~* Has a normal 12-lead electrocardiogram (ECG)~* Is a nonsmoker~Exclusion Criteria:~* Has secondary hypertension~* Has orthostatic hypotension~* Has estimated glomerular filtration rate (eGFR) of \<60 mL/min/1.73m\^2~* Recently received an investigational agent~* Has diabetes mellitus~* Has history of any cardiovascular event~* Has history of intolerance to SC injection(s)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: SAD: ALN-AGT01 (Type: EXPERIMENTAL): Participants will be administered a single dose of ALN-AGT01.
- Part A: SAD: ALN-AGT01-Matching Placebo (Type: PLACEBO_COMPARATOR): Participants will be administered a single dose of ALN-AGT01-matching placebo.
- Part B: SD: ALN-AGT01 (Type: EXPERIMENTAL): Participants with controlled salt intake will be administered a single dose of ALN-AGT01.
- Part B: SD: ALN-AGT01-Matching Placebo (Type: PLACEBO_COMPARATOR): Participants with controlled salt intake will be administered a single dose of ALN-AGT01-matching placebo.
- Part D: MD: ALN-AGT01 + Irbesartan-Matching Placebo (Type: EXPERIMENTAL): Participants, who are obese, will be administered multiple doses of ALN-AGT01 and irbesartan-matching placebo.
- Part D: MD: ALN-AGT01-Matching Placebo + Irbesartan (Type: ACTIVE_COMPARATOR): Participants, who are obese, will be administered multiple doses of ALN-AGT01-matching placebo and irbesartan.
- Part E: Open Label: ALN-AGT01 + Irbesartan (Type: EXPERIMENTAL): Participants will be administered a single dose of ALN-AGT01 and multiple doses of irbesartan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed inform consent form.~2. Age \>= 18 years and \<= 70 years.~3. Histologically or cytologically confirmed small cell lung cancer.~4. ED-SCLC according to Veterans Administration Lung Study Group.~5. Radiographically progression following a platinum-based standard prior chemotherapy regimen.~6. Eastern Cooperative Oncology Group performance status of 0 or 1.~7. Measurable disease as defined by RECIST v1.1.~8. Life expectancy \>= 8 weeks.~9. Adequate hematologic and end organ function.~Exclusion Criteria:~1. Histologically or cytologically confirmed mixed non-small cell and small cell carcinoma.~2. Prior exposure to therapeutic anticancer vaccines; prior exposure to any T cell co-stimulatory therapy or immune checkpoint inhibitors, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies.~3. Prior exposure to anti-VEGF or anti-VEGFR therapy.~4. Active brain metastasis or meningeal metastasis.~5. Clinically significant third space effusion (e.g., uncontrolled pericardial effusion, ascites or pleural effusion by extraction or other treatment).~6. Known hypersensitivity to study drug or any of its excipients; known hypersensitivity to any antibody.~7. Treatment with any other investigational agent or participation in another clinical trial within 4 weeks prior to screening.~8. Other conditions that the investigator thinks unsuitable in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
- B (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (5 Days on, 2 Days off)
- C (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (7 Days on, 7 Days off)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete